Ffects Of Mntnhex-2-Pyp On Markers Of Inflammation And Lipid Peroxidation In Asthma Mice Model

Veneta Lyubenova Shopova, Lyudmil Georgiev Terziev, Violeta Yordanova Dancheva, Galya Tzvetanova Stavreva, Milena Atanasova Atanasova, Angelina Milcheva Stoyanova, Tzvetan Hristophorov Lukanov


Background and objective: Iinvestigation of the effects of MnTnHex-2-PyP on some markers of inflammation and lipid peroxidation in an asthma mice model.

Methods: The experiment was carried out on 24 female mice C57Bl/6, divided into four groups: group 1, controls; group 2, injected with ovalbumin (OVA); group 3, treated with MnTnHex-2-PyP and group 4, treated with OVA and MnTnHex-2-PyP. The animals from groups 1 and 3 were injected i.p. on days 0 and 14 with a 100 μl phosphate-buffered saline (PBS), and those from groups 2 and 4 were injected with a 100 μl ovalbumin solution, containing 20 μg OVA. On days 24, 25 and 26 the mice from groups 1 and 2 were inhaled with PBS for 30 min, and those from groups 2 and 4 were given a 1% ovalbumin solution. One hour before inhalation, and 12 hours later the animals from groups 1 and 2 were injected i.p. with 100 μl PBS, and those from groups 3 and 4 received a 100 μl MnTnHex-2-Pyp solution in PBS сontaining 0.05mg/kg.

Results: Ovalbumin alone (group 2) increased the total cell number, total protein content, the levels of IL-4, IL-5 and 8-isoprostane in bronchoalveolar lavage. Elevations were observed in IgE level in serum, and the malone dialdehyde (MDA) content in the lung homogenate. These markers were decreased significantly in group 4 as compared to the OVA group.

Conclusions: MnTnHex-2-Pyp reduces the inflammation and lipid peroxidation in Ovalbumin-induced mice asthma model.


Asthma, BALF, Inflammation, Lipid Peroxidation, Lung Homogenate, Mntnhex-2-Pyp

Full Text:



Buhl R, A Meyer, and C Volgelmeier. Oxidant-Protease interaction in the lung prospects for antioxidant therapy. Chest. 110, Dec., 1996: 267S-272S.

Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 8, March, 2008: 183-192.

Dworski R. Oxidant stress in asthma. Thorax. 55 (Suppl. 2), Oct., 2000: S51-S53.

MacNee W. Oxidative stress and lung inflammation in airways disease. EJP. 429, Oct., 2001: 195-207.

Ciencewicki J, S Trivedi, and SR Keeberger. Oxidants and the pathogeneses of lung diseases. J Allergy Clin Immunol. 122(3), Sept, 2008: 122: 456-68.

Beasley R, J Crane, CK Lai, and N Pearce. Prevalence and etiology of asthma. J Allergy Clin Immunol. 105 (2Pt2), Feb., 2000:466-72.

Bousquet J, PK Jeffery, WW Busse, et al. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med. 161 (5), May, 2000: 1720-45.

Kay AB. Asthma and inflammation. J Allergy Clin Immunol. 87 (5), May, 1991: 893-910.

Calhoun WJ, HE Reed, DR Moest, et al. Enhanced superoxide production by alveolar macrophages and air-space cells, airway inflammation, and alveolar macrophage density changes after segmental antigen bronchoprovocation in allergic subjects. Am Rev Respir Dis. 145 (2Pt1), Feb., 1992: 317-325.

Sedgwick JB, KM Geiger, and WW Busse. Superoxide generation by hypodense eosinophils from patients with asthma. Am Rev Respir Dis. 142 (1), Jul., 1990: 120-125.

Goodyear-Bruch PG, and JD Pierce. Oxidative stress in critically ill patients. Am J Crit Care. 11 (6), Nov., 2002: 543-552.

Saltini C, AJ Hance, VJ Ferrance, et al. Accurate Quantification of Cells Received by Bronchoalveolar Lavage. Am Rev Respir Dis. 130 (4), Oct., 1984: 650-656.

Lowry OH, NJ Rosenhbrough, NJ Farr, et al. Protein measurement with the Folin phenol reagent. J Biol Chem. 193, Nov.1951: 265-275.

Ohkawa H, N Ohishi, and K Iagi. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 95 (2), June, 1979: 351-358.

Cho YS, J Lee, TH Lee, et al. Alpha-Lipoic acid inhibits airway inflammation and hyperresponsiveness in a mouse model of asthma. J Allergy Clin Immunol. 114 (2), Aug., 2004: 429-435.

Lee YC, KS Lee, SJ Park, et al. Blockade of airway hyperresponsiveness and inflammation in a murine model of asthma by a prodrug of cysteine, L-2-oxothiazolidine-4-carboxylic acid. FASEB J. 18, Sept., 2004: 1917-1919.

Pollard JM, JS Reboucas, A Durazo, et al. Radioprotective effects of manganese-containing superoxide dismutase mimics on ataxia-telangiectasia cells. Free Radic Biol Med. 47 (3), Aug., 2009: 250-260.

Saba H, I Batinić-Haberle, S Munusamy, et al. Manganese porphyrin reduces renal injury and mitochondrial damage during ischemia/reperfusion. Free Radic Biol Med. 42 (10), May, 2007: 1571-1578.

Batinić-Haberle I, I Spasojevic, RD Stevens, et al. Manganese(III) meso tetrakis ortho N-alkylpyridins:synthesis, characterization and catalysis of O‾ dismutation. J Chem Soc Dalton Trans. 2002: 2689-2696.

Okado-Matsumoto A, I Batinić-Haberle, I Fridovich. Complemantation of SOD deficient Escherichia coli by manganese porphyrin mimics of superoxide dismutase. Free Rad Biol Med. 37 (3), Aug., 2004: 401-410.

Gauter-Fleckenstein B, K Fleckenstein, K Owzar, et al. Comparison of two Mn porphyrin-based mimics of superoxide dismutase in pulmonary radioprotection. Free Radic Biol Med. 44 (6), March, 2008: 982-989.

Spasojević I, Y Chen, TJ Noel, et al. Pharmacokinetics of the potent redox-modulating manganese porphyrin, MnTE-2-PyP5+, in plasma and major organs of B6C3F1 mice. Free Radic Biol Med. 45 (7), Oct., 2008: 943-949.

Batinić-Haberle I, JS Reboucas, I Spasojevic. Superoxide Dismutase Mimics:Chemistry, Pharmacology, and Therapeutic Potencial. Antioxid Redox Signal. 13 (6), Sept., 2010: 877-917.

Li QY, C Pedersen, BJ Day, et al. Dependence of excitotoxic neurodegeneration on mitochondrial aconitase inactivation. J Neurochem. Aug. 78 (4), 2001: 746-755.

Chang LY, and JD Crapo. Inhibition of Airway Inflammation and hyperreactivity by a Catalytic Antioxidant. Chest. 123 (3), March , 2003: 446S.

Chang L Y, and JD Crapo. Inhibition of airway inflammation and hyperreactivity by an antioxidant mimetic. Free Radic Biol Med. 33 (3), Aug, .2002: 379-386.

Emelyanov A, G Fedoseev, A Abulimity, et al A. Elevated concentrations of exhaled hydrogen peroxide in asthmatic patients. Chest. 120 (4), Oct. , 2001: 1136-1139.

Bowler RP. Oxidative stress in the pathogenesis of asthma. Curr Allergy Asthma Rep. 4 (2), March , 2004: 116-122.

Matsunaga K, S Yanagisawa, T Ichikawa, et al. Airway cytokine expression measured by means of protein array in exhaled breath condensate. Correlation with physiologic properties in asthmatic patients. J Allergy Clin Immunol. 118 (1), Jul.р 2006: 84-90.

Nadeem A, SK Chhabra, A Massod, et al. Increased oxidative stress and altered levels of antioxidants in asthma. J Allergy Clin Immunol. 111 (1), Jan., 2003: 72-78.

Patel M, and BJ Day. Metalloporphyrin class of therapeutic catalytic antioxidants. Trends Pharmac Sci. 20 (9), Sept., 1999: 359-364.

Batinić-Haberle I. Manganese porphyrins and related compounds as mimics of superoxide dismutase. Methods Enzymol. 2002; 349: 223-33.

Spasojevich I, I Batinić-Haberle, JS Rebouças, et al. Electrostatic contribution in the catalysis of O2•‾ dismutation by superoxide dismutase mimics. J Biol Chem. 278 (9), Feb.,2003: 6831-6837.

Day BJ, I Batinić-Haberlen and J Crapo. Metalloporphyrins are potent inhibitors of lipid peroxidation. Free Rad Biol Med. 26 (5-6), March, 1999: 730-736.

Batinić-Haberle I, S Cuzzocrea, J Rebucas, et al. Pure MnTBAP selectively scavenges peroxynitrite over superoxide: Comparison of pure and commercial MnTBAP samples to MnTE-2-PyP in two models of oxidative stress injury an SOD-specific Escherichia coli model and carrageenan-induced pleurisy. Free Rad Biol Med. 46 (2), Jan, 2009: 192-201.

Ferrer-Sueta G, L Hannibal, I Batinić-Haberle, et al. Reduction of manganese porphyrins by flavoenzymes and submitochondrial particles: a catalytic cycle for the reduction of peroxynitrite. Free Raic Biol Med. 41 (3), Aug., 2006: 503-512.

Kachadourian R, CA Johnson, E Min, et al. Flavin-dependent antioxidant properties of a new series of meso-N,N'-dialkyl-imidazolium substituted manganese(III) porphyrins. Biochem Pharmacol. 67 (1), Jan., 2004: 77-85.

DOI: http://dx.doi.org/10.12955/emhpj.v2i0.339


  • There are currently no refbacks.

Print ISSN 1804-5804, Online ISSN 1804-9702

(c) 2018 CBU,o.p.s.